• Policy
• The MOHW has won the original drug price lawsuit
• by Lee, Jeong-Hwan Jan 25, 2022 05:55am

• Company
• United to complete P2T enrollment for its inhaled Covid drug
• by Lee, Seok-Jun Jan 25, 2022 05:55am

• Policy
• MFDS has completed verification of the efficacy of Retevmo
• by Lee, Tak-Sun Jan 25, 2022 05:55am

• Company
• Hanmi & Celltrion are producing generic COVID tx
• by Chon, Seung-Hyun Jan 25, 2022 05:55am

• Company
• Sales of SGLT-2 diabetes drugs surpassed 150 billion won
• by Ji Yong Jun Jan 24, 2022 05:56am

• Two points to note in Kymriah’s reimbursement process
• by Eo, Yun-Ho Jan 24, 2022 05:56am

• Company
• BI-Boryung concludes copromotion deal for NOAC ‘Pradaxa’
• by Kim, Jin-Gu Jan 24, 2022 05:56am

• Company
• The growth rate of the DPP-4i market increased slightly
• by Ji Yong Jun Jan 24, 2022 05:55am

• Policy
• Xeloda in breast cancer patients is also reimbursed
• by Lee, Hye-Kyung Jan 24, 2022 05:55am

• Policy
• Improve the reimb system to accommodate high-priced drugs
• by Lee, Hye-Kyung Jan 21, 2022 05:56am